Jiang Bincan, Chen Ziyang, Zhou Jiajie
Cancer Research Institute, Hengyang Medical School, University of South China, Hengyang, Hunan Province 421001, China.
Cancer Research Institute, Hengyang Medical School, University of South China, Hengyang, Hunan Province 421001, China.
Comput Biol Chem. 2024 Dec;113:108229. doi: 10.1016/j.compbiolchem.2024.108229. Epub 2024 Oct 5.
Lower-grade glioma (LGG) refers to WHO grade 2 and 3 gliomas. Surgery combined with radiotherapy and chemotherapy can significantly improve the prognosis of LGG patients, but tumor progression is still unavoidable. As a form of posttranscriptional regulation, RNA editing (RE) has been reported to be involved in tumorigenesis and progression and has been intensively studied recently.
Survival data and RE data were subjected to univariate and multivariate Cox regression analysis and lasso regression analysis to establish an RE risk score model. A nomogram combining the risk score and clinicopathological features was built to predict the 1-, 3-, and 5-year survival probability of patients. The relationship among ADAR1, SOD2 and SOAT1 was verified by reverse transcription-quantitative polymerase chain reaction (RT-qPCR) RESULTS: A risk model associated with RE was constructed and patients were divided into different risk groups based on risk scores. The model demonstrated strong prognostic capability, with the area under the ROC curve (AUC) values of 0.882, 0.938, and 0.947 for 1-, 3-, and 5-year survival predictions, respectively. Through receiver operating characteristic curve (ROC) curves and calibration curves, it was verified that the constructed nomogram had better performance than age, grade, and risk score in predicting patient survival probability. Apart from this functional analysis, the results of correlation analyses between risk differentially expressed genes (RDEGs) and RE help us to understand the underlying mechanism of RE in LGG. ADAR may regulate the expression of SOD2 and SOAT1 through gene editing.
In conclusion, this study establishes a novel and accurate 17-RE model and a nomogram for predicting the survival probability of LGG patients. ADAR may affect the prognosis of glioma patients by influencing gene expression.
低级别胶质瘤（LGG）指世界卫生组织（WHO）2级和3级胶质瘤。手术联合放疗和化疗可显著改善LGG患者的预后，但肿瘤进展仍不可避免。作为一种转录后调控形式，RNA编辑（RE）已被报道参与肿瘤发生和进展，且最近受到了深入研究。
对生存数据和RE数据进行单因素和多因素Cox回归分析以及套索回归分析，以建立RE风险评分模型。构建一个结合风险评分和临床病理特征的列线图，用于预测患者1年、3年和5年的生存概率。通过逆转录定量聚合酶链反应（RT-qPCR）验证ADAR1、SOD2和SOAT1之间的关系。
构建了一个与RE相关的风险模型，并根据风险评分将患者分为不同的风险组。该模型显示出强大的预后能力，1年、3年和5年生存预测的ROC曲线下面积（AUC）值分别为0.882、0.938和0.947。通过受试者工作特征曲线（ROC）和校准曲线验证，所构建的列线图在预测患者生存概率方面比年龄、分级和风险评分具有更好的性能。除了这种功能分析外，风险差异表达基因（RDEG）与RE之间的相关性分析结果有助于我们了解RE在LGG中的潜在机制。ADAR可能通过基因编辑调节SOD2和SOAT1的表达。
总之，本研究建立了一种新颖且准确的17-RE模型和列线图，用于预测LGG患者的生存概率。ADAR可能通过影响基因表达来影响胶质瘤患者的预后。
